Russell Clayton
Technik-/Wissenschafts-/F&E-Leiter bei LARIMAR THERAPEUTICS, INC.
Vermögen: 142 425 $ am 30.04.2024
Profil
Russell G.
Clayton is currently the Chief Medical Officer at Larimar Therapeutics, Inc. He previously worked as the Regional Medical Director-Scientific Affairs at Merck & Co., Inc., Director-Asthma Program Division at The Children's Hospital of Philadelphia Foundation, Vice President-Research & Development at Windtree Therapeutics, Inc., and Chief Medical Officer at Alcresta Therapeutics, Inc. He received his undergraduate degree from LaSalle University and his doctorate from Philadelphia College of Osteopathic Medicine.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 17.01.2024 | 22 500 ( 0,04% ) | 142 425 $ | 30.04.2024 |
Aktive Positionen von Russell Clayton
| Unternehmen | Position | Beginn |
|---|---|---|
| LARIMAR THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 17.07.2023 |
Ehemalige bekannte Positionen von Russell Clayton
| Unternehmen | Position | Ende |
|---|---|---|
Alcresta Therapeutics, Inc.
 Alcresta Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Alcresta Therapeutics, Inc. engages in the development of enzyme-based products designed to address challenges faced by people living with gastrointestinal disorders and rare diseases. It offers products designed to improve the delivery, digestion, and absorption of long-chain polyunsaturated fatty acids or LCPUFAs. The company was founded by Robert Gallotto and Dr. Alexey L. Margolin in 2011 and is headquartered in Newton, MA. | Technik-/Wissenschafts-/F&E-Leiter | 01.04.2017 |
| MERCK & CO., INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
The Children's Hospital of Philadelphia Foundation
 The Children's Hospital of Philadelphia Foundation Hospital/Nursing ManagementHealth Services The Children's Hospital of Philadelphia Foundation operates charitable organizations for children's health care. It conducts programs on patient care, research, and clinical education. The company was founded in 1855 and is headquartered in Philadelphia, PA. | Corporate Officer/Principal | - |
| WINDTREE THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Russell Clayton
| LaSalle University | Undergraduate Degree |
| Philadelphia College of Osteopathic Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| WINDTREE THERAPEUTICS, INC. | Health Technology |
| MERCK & CO., INC. | Health Technology |
| LARIMAR THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
The Children's Hospital of Philadelphia Foundation
The Children's Hospital of Philadelphia Foundation Hospital/Nursing ManagementHealth Services The Children's Hospital of Philadelphia Foundation operates charitable organizations for children's health care. It conducts programs on patient care, research, and clinical education. The company was founded in 1855 and is headquartered in Philadelphia, PA. | Health Services |
Alcresta Therapeutics, Inc.
Alcresta Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Alcresta Therapeutics, Inc. engages in the development of enzyme-based products designed to address challenges faced by people living with gastrointestinal disorders and rare diseases. It offers products designed to improve the delivery, digestion, and absorption of long-chain polyunsaturated fatty acids or LCPUFAs. The company was founded by Robert Gallotto and Dr. Alexey L. Margolin in 2011 and is headquartered in Newton, MA. | Health Technology |
